Cargando…
Representativeness of European clinical trial populations in mild Alzheimer’s disease dementia: a comparison of 18-month outcomes with real-world data from the GERAS observational study
BACKGROUND: Comparison of disease progression between placebo-group patients from randomised controlled trials (RCTs) and real-world patients can aid in assessing the generalisability of RCT outcomes. This analysis compared outcomes between community-dwelling patients with mild Alzheimer’s disease (...
Autores principales: | Reed, Catherine, Belger, Mark, Dell’Agnello, Grazia, Kahle-Wrobleski, Kristin, Sethuraman, Gopalan, Hake, Ann, Raskin, Joel, Henley, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5883304/ https://www.ncbi.nlm.nih.gov/pubmed/29615123 http://dx.doi.org/10.1186/s13195-018-0360-4 |
Ejemplares similares
-
Disease Progression in Mild Dementia due to Alzheimer Disease in an 18-Month Observational Study (GERAS): The Impact on Costs and Caregiver Outcomes
por: Jones, Roy W., et al.
Publicado: (2017) -
Caregiver Burden in Alzheimer's Disease: Differential Associations in Adult-Child and Spousal Caregivers in the GERAS Observational Study
por: Reed, Catherine, et al.
Publicado: (2014) -
How to deal with missing longitudinal data in cost of illness analysis in Alzheimer’s disease—suggestions from the GERAS observational study
por: Belger, Mark, et al.
Publicado: (2016) -
Potential cost savings to be made by slowing cognitive decline in mild Alzheimer’s disease dementia using a model derived from the UK GERAS observational study
por: Lenox-Smith, Alan, et al.
Publicado: (2018) -
Resource utilisation, costs and clinical outcomes in non-institutionalised patients with Alzheimer’s disease: 18-month UK results from the GERAS observational study
por: Lenox-Smith, Alan, et al.
Publicado: (2016)